BioNTech (BNTX) Competitors

GSK (NYSE:GSK) and BioNTech (NASDAQ:BNTX) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment, community ranking and analyst recommendations.

Do insiders and institutionals hold more shares of GSK or BNTX?

15.7% of GSK shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 10.0% of GSK shares are owned by company insiders. Comparatively, 19.2% of BioNTech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Does the MarketBeat Community prefer GSK or BNTX?

GSK received 682 more outperform votes than BioNTech when rated by MarketBeat users. Likewise, 57.12% of users gave GSK an outperform vote while only 46.05% of users gave BioNTech an outperform vote.

Company	Underperform	Outperform
GSK	Outperform Votes 822 57.12%	Underperform Votes 617 42.88%
BioNTech	Outperform Votes 140 46.05%	Underperform Votes 164 53.95%

Does the media prefer GSK or BNTX?

In the previous week, GSK had 40 more articles in the media than BioNTech. MarketBeat recorded 48 mentions for GSK and 8 mentions for BioNTech. BioNTech's average media sentiment score of 0.81 beat GSK's score of 0.24 indicating that BioNTech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	20 Very Positive mention(s)	1 Positive mention(s)	19 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
BioNTech	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Do analysts rate GSK or BNTX?

GSK presently has a consensus price target of $43.25, indicating a potential upside of 13.91%. BioNTech has a consensus price target of $142.72, indicating a potential upside of 27.93%. Given BioNTech's stronger consensus rating and higher possible upside, analysts clearly believe BioNTech is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	0 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	3 Strong Buy rating(s)	2.60
BioNTech	0 Sell rating(s)	3 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Is GSK or BNTX more profitable?

GSK has a net margin of 8.13% compared to BioNTech's net margin of -15.16%. GSK's return on equity of 48.59% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	8.13%	48.59%	11.11%
BioNTech	-15.16%	-2.35%	-2.05%

Is GSK or BNTX a better dividend stock?

GSK pays an annual dividend of $1.57 per share and has a dividend yield of 4.1%. BioNTech pays an annual dividend of $1.53 per share and has a dividend yield of 1.4%. GSK pays out 98.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. BioNTech pays out -72.9% of its earnings in the form of a dividend.

Which has higher valuation and earnings, GSK or BNTX?

GSK has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$31.38B	2.51	$3.29B	$1.59	23.88
BioNTech	$3.04B	8.80	$1.01B	-$2.10	-53.12

Which has more volatility and risk, GSK or BNTX?

GSK has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, BioNTech has a beta of 0.17, indicating that its stock price is 83% less volatile than the S&P 500.

Summary

GSK beats BioNTech on 14 of the 21 factors compared between the two stocks.